Angany announces First-in-Human Clinical Study on ANG-101, a Vaccine Candidate to Treat Cat Allergy

9 October 2023

October 3, 2023 – Angany Inc., announces that it has received clearance (Notice of Acceptance) from MHRA (Medicines and Healthcare Products Regulatory Agency) for the first clinical study to be conducted on its vaccine candidate ANG-101 to treat human allergy to cats. This clinical study is a First in Human, open label and single site evaluation of the safety, allergenicity and immunogenicity of the new vaccine in adult patients allergic to cat dander and will be conducted under the guidance of Professor Stephen Durham and Dr Guy Scadding, two leading clinical allergy experts from Imperial College London.

To know more